ELEVIDYS is a prescription gene therapy used to treat ambulatory and non-ambulatory individuals at least 4 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene. Use in non-ambulatory individuals is approved under accelerated approval. Accelerated approval allows for drugs to be approved based on a marker that is considered reasonably likely to predict a cl
inical benefit. ELEVIDYS treatment increased the marker, ELEVIDYS micro-dystrophin in skeletal muscle. Verification of a clinical benefit may be needed for ELEVIDYS to continue to be approved for non-ambulatory patients with DMD. Individuals with any deletion in exon 8 and/or exon 9 in the DMD gene should not receive ELEVIDYS. Please see full Important Safety Information at elevidys.com/ISI and full Prescribing Information at elevidys.com/pi. Our page is intended to help individuals with Duchenne, their caregivers and families get to know ELEVIDYS. The posts on this page are not meant to be medical advice or treatment recommendations. Your healthcare provider should always be your main resource for any questions about your health and medical care. This page is intended for US audiences only. If you have questions about ELEVIDYS, support is available. Visit elevidys.com/support/sareptassist or contact Sarepta at 1-888-SAREPTA (1-888-727-3782).
